
|Articles|September 1, 2003
BOTOX and Prostate
Botulinum toxin injected into the prostate reduced symptoms of benign prostatic hyperplasia (BPH) and prostate-specific antigen (PSA) levels and was well tolerated, according to the results of a randomized, placebo-controlled, preliminary trial (Urology 2003; 62:259-265).
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
2
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
3
Phase 2 Nemolizumab Trial Opens for CPUO
4
Balancing Pathophysiology and Patient Lifestyle in Acne Management: Part 1
5


















